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Abstract: The reaction products of electrophiles in vivo can be measured as adducts to the abundant
proteins, hemoglobin (Hb), and human serum albumin (HSA), in human blood samples. During the
last decade, methods for untargeted screening of such adducts, called “adductomics”, have used
liquid chromatography-mass spectrometry to detect large numbers of previously unknown Hb and
HSA adducts. This review presents methodologies that were developed and used in our laboratories
for Hb and HSA adductomics, respectively. We discuss critical aspects regarding choice of target
protein, sample preparation, mass spectrometry, data evaluation, and strategies for identification of
detected unknown adducts. With this review we give an overview of these two methodologies used
for protein adductomics and the precursor electrophiles that have been elucidated from the adducts.
Keywords: proteins; protein adducts; electrophiles; adductomics; mass spectrometry; hemoglobin;
human serum albumin
1. Introduction
Electrophilic compounds occurring in vivo are generally formed by metabolism of molecules
arising from endogenous (e.g., oxidative stress) and exogenous (e.g., diet and drugs) sources.
Since these reactive species can modify nucleophilic sites of DNA and functional proteins, they
can have toxicological implications. The inherent reactivity of electrophiles makes them difficult to
measure in vivo due to their short lifetimes, which has initiated analytical developments to measure
their adducts to biomacromolecules. Thus, since the 1970s researchers have studied adducts of reactive
electrophiles with abundant blood proteins, to obtain information about cumulative exposures to these
reactive species over the mean residence times of particular proteins [1–3]. Protein adducts are covalent
modifications resulting from reactions between electrophiles and nucleophilic sites in proteins, such as
the N-terminus or the amino acid side chains containing sulfhydryl or amine functionalities.
Since the early days of adduct measurements, mass spectrometry (MS) has been the analytical
detection technique of choice for the adduct measurements because it provides both qualitative and
quantitative information about the modified proteins. Measurements were targeted on adducts from
expected reactive metabolites of toxic chemicals with a given protein. Important examples include
hemoglobin (Hb) adducts from ethylene oxide [4,5], aromatic amines [6,7], and acrylamide [8,9] in
occupational exposed workers and in smokers. Well-known examples of adducts measured to human
serum albumin (HSA) are adducts of benzene and styrene in factory workers [10,11]. Many studies also
showed a background adduct level in non-exposed control persons, as exemplified with the Hb adducts
from acrylamide, shown to be associated with consumption of cooked foods [12], and HSA adducts of
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aflatoxin B1 from consumption of mycotoxin-contaminated foods [13,14]. These early studies clearly
showed that humans have a continuous background exposure to electrophiles, both from endogenous
and exogenous sources.
During the last decade there has been a transition to untargeted approaches, “adductomics”,
for analysis of the totality of adducts bound to a particular nucleophilic site [15] with the aim to
contribute to the characterization of the human exposome [16]. The adductomics concept was first
described by Kanaly et al. in 2006, who reported the simultaneous LC-MS detection of numerous DNA
adducts in human tissues [17]. A few years later, similar LC-MS approaches were described for protein
adductomics by Li et al. [18] focusing on Cys34 adducts of HSA [15] and by Carlsson et al. [19] using
N-terminal valine adducts of Hb [20]. These latter two groups, at the University of California, Berkeley
and Stockholm University, have continued to pursue adductomics of HSA and Hb, respectively.
This review compares the two methodologies and lists the electrophilic species that have been
characterized. For an updated and comprehensive overview of DNA adductomics the recent review
by Villalta and Balbo is recommended [21].
2. Choice of Target Proteins in Blood
Most electrophiles occurring in vivo are generated from enzymatic biotransformations of
precursor molecules as well as from reactive oxygen and carbonyl species. Reactive functional groups
make electrophiles capable of reacting with nucleophilic loci of proteins, notably, oxygen radicals,
epoxides (adducts formed via nucleophilic substitution), activated double bonds of α,β-unsaturated
carbonyl compounds (adducts formed via Michael addition), and aldehydes (adducts are Schiff bases
formed via carbinolamine intermediates) [22,23]. Important nucleophilic sites for adduct formation
in proteins are the sulfhydryl group of cysteine and amine functionalities of histidine, lysine, and
N-terminal amino acids [23]. Factors that affect the extent of adduct formation are the nucleophilicity
and pKa of the nucleophile and steric factors that influence the access of the reactive electrophile to
the nucleophilic site. Nucleophilic sites that are deprotonated at physiological pH (7.4) are favored
for adduction because they have free electron pairs that can participate in the formation of covalent
bonds. Because the chemistry of adduct formation differs across nucleophilic sites, for example Schiff
bases are formed by reactions of aldehydes with amines and the formation of disulfide adducts require
free sulfhydryl groups, it would be optimal to include several nucleophilic sites in characterizing a
protein adductome.
Important properties of Hb and HSA are summarized in Table 1. Regarding HSA, Cys34 has
been the focus of all published studies on HSA adductomics thus far. This cysteine accounts for the
antioxidant and detoxifying properties of albumin in the interstitial space and, therefore, is highly
conserved in all mammalian species [24,25]. Because Cys34 has an unusually low pKa of 6.55, compared
to 8.0–8.55 for most protein thiols [25,26], the sulfhydryl group is predominantly in the deprotonated
thiolate form (S-) at physiological pH (7.4). Since thiolate is an unusually strong nucleophile, many
small electrophiles react preferentially at this site and makes Cys34 an exceptional nucleophilic locus
for adductomics [15].
With a few exceptions the in vivo formation of adducts involves only a very small fraction of the
total amount of protein. For example, levels of typical Hb adducts of N-terminal valine (30–150 pmol/g
Hb) correspond to 5–25 adducted Hb chains per 107 Hb chains in a human blood sample, whereas
HSA adduct levels to Cys34 of 0.5–50 nmol/g HSA correspond to 3 modified HSA molecules per
103–105 HSA molecules. Furthermore, since blood is the only tissue that is routinely available in studies
of human health, adduct measurements have thus far focused on the two most abundant proteins
in blood, i.e., Hb and HSA. The concentrations of Hb and HSA in human blood are approximately
120–160 mg/mL and 35–55 mg/mL, respectively, which enable adductomic analysis using between 5
(HSA) and 250 µL (Hb) of blood per subject. In contrast, the concentration of DNA in human blood is
about 30 µg/mL, and DNA adductomics requires about 10 mL blood [27] per subject.
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Table 1. Properties of hemoglobin and human serum albumin.
Property Human Hemoglobin Human Serum Albumin
Molecular weight
Tetramer, 64 kDa. Composed of
two α- and two β-subunits (in
adult Hb), both weighing 16 kDa
67 kDa
Main functions Oxygen transport
Transport of e.g., hormones and
fatty acids, maintains oncotic
pressure, antioxidant.
Localization Red blood cells Blood plasma
Conc (mg/mL) 120–160 (in blood) 35–55 (in serum)
Turnover rate (days) ~120 (lifespan of red blood cells) ~20 (half-life in serum)
Another important factor is the life-time of the protein in the human body, which provides a time
window for integration of chronic exposures to reactive species [23,28]. Human serum albumin has
a half-life of approximately 20 days [24] and Hb has a life-time (the same as the erythrocytes) of
approximately 120 days [29]. Chemically stable adducts of these proteins accumulate during chronic
exposure and such adducts of HSA and Hb reach steady-state levels corresponding to the exposure
during about one and two months, respectively [23,28]. This “signal-averaging” reduces variability
due to short-term variation in exposure to reactive species and provides more stable measures of
long-term exposure for epidemiologic investigations [30]. In contrast, DNA adducts are more variable
measures of exposure because of complex kinetics and turnover rates due to enzymatic repair of
adducts, and result in low levels of accumulation [23,31].
The adductomics of Hb has focused exclusively on adducts to the N-terminal Val, which has a
pKa of approximately 7.8 (α-chain) and 6.8 (β-chain) [32]; Hb is a tetramer composed of two α- and
two β-chains, both with Val as the N-terminal amino acid. Another nucleophilic amino acid in Hb of
potential interest for adductomic studies is β-Cys93, which is a known adduction site for aromatic
amines [7,33]. An important difference between HSA and Hb is the localization of the two proteins;
HSA is, except in blood, also found in the interstitial fluid whereas Hb is only found in red blood cells
(RBCs). Their chemical environments are therefore partly different, which could give effects on the
adductomes observed. In RBCs, the concentration of glutathione (GSH) is high compared to plasma
concentrations (about 250 times higher in RBCs [34]), meaning that GSH has a far more important
role as an electrophile scavenger in RBCs, giving some protection of Hb from incoming electrophiles.
In plasma, Cys34 of HSA has a similar function. The sulfhydryl of Cys34 is a stronger and larger
nucleophile than the amino group of N-terminal Hb Val, also with a lower pKa, meaning that higher
adduct levels are to be expected to this nucleophilic site. This is confirmed when comparing adduct
levels from a few electrophilic precursors in the published adductomics studies, with Hb adduct levels
typically in the pmol/g Hb range and HSA adduct levels in the nmol/g HSA range. In fact, the human
in vivo reaction rate between benzene oxide and HSA Cys34 was 30 times greater than that for Hb
β-Cys93 [35]. This also means that much lower sample volumes may be used for analysis of HSA
adducts compared to Hb adducts.
3. Sample Preparation
In this section we describe and compare the sample preparation procedures for HSA and Hb
adductomics [36,37]. Critical differences between the two methodologies are summarized in Table 2.
The method for HSA adductomics uses only 5 µL of plasma/serum. The first step in the sample
preparation involves precipitation of non-HSA proteins with 60% methanol. Following centrifugation,
the protein content of the supernatant is approximately 70% HSA (of total protein content) [36].
A portion of the supernatant is diluted with buffer and digested with trypsin, using a pressurized
system (Barozyme HT48 from Pressure Biosciences Inc., South Easton, MA, USA) that facilitates
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complete digestion in 30 min, without prior reduction of the intramolecular HSA disulfides.
The Cys34 residue is located on the third largest tryptic peptide, designated T3 with sequence
21ALVLIAFAQYLQQC34PFEDHVK41 with MW 2432.2562 Da (Figure 1). After digestion, formic acid is
added to the sample to prevent further degradation. Prior to LC-MS analysis, a portion of the digest is
diluted with 2% ACN/0.2% formic acid, and an isotopically labelled T3 peptide is added as an internal
standard to monitor retention time drift and mass accuracy. Quantitation of adducts is performed
relative to a housekeeping (HK) peptide, which is an HSA peptide of sequence 41LVNEVTEFAK50
with MW 1148.6077 Da. The peak area ratio (PAR = adduct peak area/HK peptide peak area) has been
shown to be a reliable measure of adduct concentration over a wide dynamic range [36]. Recently the
method has been adapted for analysis of HSA extracted from dried blood spots (DBS), which require
additional steps prior to digestion [38]. The small amount of protein needed for HSA adductomics,
as well as the possibility to use DBS for the analysis, is an attractive advantage of this methodology.
The fast sample preparation allows for processing and MS analysis of about 12 samples per day
(with duplicate injections).
Table 2. Critical aspects of the methodologies for Hb and HSA adductomics.
Methodological Aspect Hb Adductomics HSA Adductomics
Nucleophilic site N-terminal Val Cys34
Sample volume 250 µL whole blood/lysate 5 µL plasma/serum
Enrichment of adducts
Detachment of adducts using the reagent
fluorescein isothiocyanate, followed by
clean-up using solid phase extraction
Precipitation of non-HSA proteins,
followed by tryptic digestion
Analytes Fluorescein thiohydantoin derivatives ofadducted Val
Tryptic peptide containing the
adducted Cys34 residue
MW of analytes >502 Da (starting at the MW of the methyladduct)
>2432 Da (analyzed as triply
charged positive ions)
Analytical method
Liquid chromatography-mass
spectrometry (LC-MS)/high-resolution MS
(LC-HRMS)
Nano-liquid
chromatography-high-resolution
mass spectrometry (nLC-HRMS)
Type of LC column Reversed phase, C18, 120 µL/min Monolithic, 750 nL/min
Type of MS and MS
method
MS: Triple quadropole in multiple reaction
monitoring mode; HRMS: Orbitrap in data
independent acquisition mode
HRMS: Orbitrap in data
dependent acquisition mode
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The methodology for Hb adductomics is based on a modified Edman procedure in which
adducted N-terminal amino acids are specifically detached using the reagent fluorescein isothiocyanate
(FITC) (Figure 2). In the 1980s, during the development of the first successful method for analysis
of N-terminal Hb adducts it was found that the detachment of adducted N-terminal Val with
isothiocyanate reagents was favored over non-adducted Val, providing a basis for selective enrichment
of adducts [39–41]. This methodology was then developed for LC-MS analysis using FITC as the
reagent [42,43]. To perform Hb adductomics 5 mg of FITC (dissolved in dimethyl sulfoxide) is
added to 250 µL of whole blood or lysate (both work equally well for the methodology) and mixed
at 37 ◦C overnight [44]. This reaction, an example of a modified Edman degradation, generates
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detached adduct derivatives, in the form of fluorescein thiohydantoins (FTHs) (Figure 2). To purify the
FTH derivatives, the proteins are first precipitated with acetonitrile (ACN) and then centrifuged.
At this step, stable isotope-substituted internal standards corresponding to one or several FTH
derivatives of known adducts are added. The FTH derivatives have a carboxylic acid functional
group (originating from the fluorescein part of the molecules), which may be protonated/deprotonated
with acids/bases. This property is utilized in the work-up of the FTHs. Following precipitation and
centrifugation, the FTH-containing ACN supernatant is alkalized (deprotonation of the carboxylic
acid) with ammonium hydroxide then added to a mixed-mode anion exchange solid phase extraction
(SPE) column. The deprotonated anionic FTHs are retained on the column, which are then washed
with ACN, H2O, and cyanoacetic acid in H2O, in that order. To elute the FTHs a solution of cyanoacetic
acid in ACN is used, which breaks both the hydrophobic and anionic interactions with the column.
The eluted samples are evaporated to dryness using air and then re-dissolved in H2O/ACN (6:4),
preparing the samples for LC-MS analysis. Although the sample processing for Hb adductomics is
more time-consuming than the method for HSA adductomics, with the over-night derivatization being
the limiting step, the method is fast compared to earlier methods for Hb adduct analysis [40,45] and is
applicable for semi-high throughput analysis [44,46].
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4. Mass Spectrometry
The method for HSA adductomics uses na fl C and nanoelectrospray-ionization and the
mass spectrometry is performed with a Hybrid Ion Trap Orbitrap high-resolution mass spectrometer
(HRMS) (ThermoFisher Scientific, MA, USA) [36]. One microliter of each sample digest is injected into
a monolithic nanoflow column that has excellent properties for separation of hydrophobic peptides
and proteins. The analysis requires about 40 min per injection, and each sample is injected in duplicate
followed by blank and wash injections, making the total time per sample about 2 h. The ionization is
done in positive-ion mode and the mass spectrometer is operated in the data-dependent acquisition
(DDA) mode, which selects the most abundant ions f r fragmen ation (MS2) us ng the ion trap.
The combin tion of high resoluti n MS1 data from the Orbitrap analysis and ion trap MS2 data,
enables the classification of unknown compounds as adducts and determination of adduct masses
with high accuracy.
Hemoglobin adductomics has almost exclusively been performed with triple quadrupole mass
spectrometers which require a different strategy for untargeted screening of adducts compared to
high resolution mass spectrometers. Similar to early methods for DNA adductomics and HSA
adductomics [17,18], the screening of N-terminal Hb adducts using triple quadrupole MS has been done
in the multiple reaction monitoring (MRM) mode [19]. From the analysis of FTH derivatives of known
N-terminal Hb adducts it was observed that all such analytes exhibit similar fragmentation pathways
when performing MS/MS, resulting in at least three common fragments (Figure 3). This observation is
the underlying principle for MRM screening of FTH derivatives of unknown N-terminal Hb adducts,
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in which sequential lists of MRM transitions are set up for the m/z range of interest with four
diagnostic fragments, corresponding to the most common fragmentation pathways, being screened for
each incremental m/z unit. Although the most sensitive alternative on a triple quadrupole platform,
the analysis of large numbers of MRM transitions is relatively slow. To acquire a sufficient number of
data points for quantitative analysis each sample needs to be injected several times, covering different
increments of the studied m/z range with each injection. In the first application of Hb adductomics
each sample was injected 12 times to cover a range of 135 m/z, demonstrating the time-consuming
aspects of this methodology [19]. Recently, the methodology has been adapted for HRMS using a
Hybrid Quadrupole Orbitrap MS (Thermo Scientific, MA, USA) [37]. On this platform the MS analysis
was performed in the data independent acquisition (DIA) mode. In this mode, all ions within a
specified m/z range are fragmented, with collective fragmentation patterns for all ions within that
range recorded. This is an advantageous approach when screening for low-level compounds, such as
adducts, in complex biological samples compared to DDA for which only abundant ions will be
fragmented, thereby risking missing interesting compounds. In a blood sample derivatized with
FITC the concentration of reagent byproducts is high (5 mg FITC is used for each 250 µL of blood;
see Sample Preparation above), making DIA a better suited alternative to DDA to maximize detection
of potential adducts. A disadvantage with DIA is that the measurements are slower than for DDA,
meaning that the samples need to be injected several times to cover large m/z ranges. When screening
the m/z range 500–700 m/z for Hb adducts each sample was injected four times, with each injection
covering 50 m/z [37]. To confirm possible adducts observed in the DIA mode, additional follow-up
measurements were performed in the parallel reaction monitoring mode, in which ions of specific m/z
(unit resolution) are fragmented.
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For Hb adductomics conventional LC-MS has been performed using a flow rate of 0.12 mL/min
and electrospray ionizatio in the positive mode [19]. A volume of 10–20 µL of the sample is injected
(depending on type of instrumentation and purpose of experiment) on a rever ed phase C18 olumn
with the dimen ions 2.1 mm × 150 mm and a gradient is applied to separ t ample components.
The chromatographic program is 35 min per injection.
5. Dat Evalu tion
Untargeted screening MS experiments generate huge and complex sets of data, that are both
difficult and time-consuming to evaluate. In comparison with metabolomics and proteomics,
adductomics is a small field of research and there are no commercial software solutions for the
evaluation of adductomic data.
For HSA adductomics, unknown species detected as triply charged ions in the HRMS are classified
as Cys34 HSA adducts if they exhibit a sufficient number of b+- and y2+-fragments that are characteristic
of the T3 peptide (m/z = 811.7594). This process is described in detail by Grigoryan et al. 2016 [36].
To facilitate this time-consuming task, in-house software, written in the programming language
R, has been developed for processing MS2 spectra according to the established rules for adduct
selection [47]. The internal standard that is added in the final step of sample preparation (isotopically
labeled T3 modified with iodoacetamide) is used to monitor variations in retention times and mass
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accuracy throughout the analysis. The resulting processed spectra are inspected manually to control
for false positives. For quantification of detected adducts, selected ion chromatograms generated using
the monoisotopic masses (MIMs) of the adducted T3 peptides are used. Peak area ratios relative to
the HK peptide facilitate relative quantitation and statistical analyses and can provide approximate
concentrations in pmol adduct/mg HSA [36]. The added masses of the adducts are calculated by
subtracting the MIM of the thiolate form of the unmodified T3 peptide from the MIM of the adducted
T3 peptides. The calculated added masses are used to propose elemental compositions of adducts and
to suggest likely structures and electrophilic precursors.
When evaluating data from Hb adductomics, adduct candidates are selected based on the
observation of at least two of the four screened diagnostic fragments (see Mass Spectrometry Analysis
above and Figure 3). Compounds considered as possible adducts are further studied in product
ion scan mode and their fragmentation patterns compared with those of known adduct analytes.
The selection of adducts is done manually. The evaluation of MRM data is time-consuming but rather
straightforward, which is not the case for DIA data for which the evaluation requires extensive manual
inspection as well as follow-up experiments to select adducts with certainty. To determine the added
mass of an adduct, the m/z of the FTH derivative of unmodified Val is subtracted from the m/z of the
FTH derivative of the Val adduct. Adduct levels of Hb adducts are estimated using a semiquantitative
approach, assuming that all FTH derivatives of Val adducts have similar responses in the MS analysis.
Internal standard calibration has been done using the stable-isotope internal standard corresponding
to the FTH derivative of the Val adduct of acrylamide (AA), which is added to all samples during
the sample preparation immediately after the FITC derivatization. A calibration curve of a reference
standard of AA-Val-FTH and the corresponding internal standard is used for this purpose. The average
of the integrated peak areas for the detected diagnostic transitions for each adduct is used for the
determinations. The adduct levels are then adjusted for the Hb concentrations in the blood samples,
measured separately using a spectrophotometric device. Adduct levels are reported in the unit pmol/g
Hb. The assumption that all FTH derivatives of Val adducts have similar responses in the MS analysis
is a simplification but a reasonable approximation for the low molecular weight adducts observed.
The supposed similar responses are supported by the comparable responses for the different known
adducts that have been studied as FTH derivatives in more detail [48–52].
6. Identification of Adducts
Following untargeted detection of adducts the next challenge is their identification. This section
describes how previously unknown adducts have been identified following HSA and Hb adductomics.
With HSA adductomics about 75 adducts (or HSA variants) have been reported thus far with added
masses ranging from −46 to 510 Da [36,53–55] (negative added masses refer to truncations and
deletions). Most of these adducts have been annotated to presumed structures and 11 have been
identified through comparisons with reference standards [36,55,56]. The HSA adducts detected in the
four published adductomics studies are presented in Table 3. Annotations include Cys34 oxidation
products, truncations and deletions, and disulfides of low-molecular-weight thiols. Many of the HSA
modifications detected through adductomics result from oxidation of Cys34 to produce adducts with
one, two or three oxygens. Because the one-oxygen addition product, i.e. the sulfenic acid (Cys34-SOH)
is unstable, it reacts with the adjacent amino acid Gln33 to produce a cyclic sulfinamide, which is
detected [56]. Formation of the Cys34 sulfenic acid, also leads to disulfide formation with small
circulating thiols, which represent the largest class of adducts detected with HSA adductomics thus far.
With Hb adductomics 25 different N-terminal Val adducts have been detected, with added masses
ranging from 15 to 198 Da, with 13 of them identified thus far [19,50,52,57]. These Hb adducts are
presented in Table 4.
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Table 3. HSA adducts detected on the T3 peptide that contain Cys34.
Adduct Ret. Time(min)
MIM Observed
(m/z, +3)
Added Mass
(Da)
Suggested Elemental Composition of
Added Mass (to Cys34S−) Annotation
796.43 a,b,d 27.5 796.4309 −45.9913 −CH2S Cys34→Gly
800.43 a,b,d 28.4 800.4317 −33.9873 −SH2 Cys34→Dehydroalanine
805.76 a,b,d,e 27.2 805.7632 −17.9965 −SH2, +O Cys34→Oxoalanine
808.73 a,b,c,d 28.3 808.7306 −9.0923 Not Cys34 adduct
810.45 a,c 30.5 810.4536 −3.9280 Not Cys34 adduct
811.43 a,b,c,d 30.4 811.4254 2431.2480 +C114H172N27O30S T3 Dimer f
811.76_1 a,b,c,d 27.9 811.7608 1.0072 +H T3 Labile adduct
811.76_2 a,b,c,d,e 28.6 811.7609 1.0097 +H Unmodified T3 f
816.42 a,b,c,d,e 27.8 816.4200 13.9766 −H2, +O S-Monooxidation f
816.43 a,b,c,d,e 29.1 816.4321 15.0233 +CH3 Methylation (not at Cys34)
820.09 a,c,d 28.8 820.0920 25.9995 +CN S-Cyanylation
822.42 a,b,c,d,e 27.7 822.4236 32.9946 +HO2 S-Dioxidation f
823.39 a 27.2 823.3971 35.9173 Not Cys34 adduct
825.76 d 26.7 825.7644 43.0188 +C2H3O S-Acetylation
826.10 d 26.7 826.0990 44.0226 +C2H4O Unknown (likely S-addition of an aldehyde)
826.44 a 27.9 826.4358 45.0332 +C2H5O Ethylene oxide adduct
827.09 b,d 28.8 827.0901 46.9960 +CH3S S-Methylthiolation
827.09 c 30.1 827.0946 47.0022 +HO2 + CH2 Cys34 sulfinic acid plus methylation (not Cys34)
827.1 d 27.5 827.0958 47.0129 +CH3O2 S-(O)-O-CH3
827.76 a,b,c,d,e 28.0 827.7550 48.9889 +HO3 S-Trioxidation f
829.13 a 27.4 829.1264 53.1052 Not Cys34 adduct
829.40 a,b 28.6 829.3972 53.9177 Not Cys34 adduct
829.44 a 28.9 829.4369 54.0366 +C3H4N Acrylonitrile adduct
830.41 d 26.5 830.4059 56.9433 Unknown
830.44 d 27.3 830.4359 57.0333 +C3H5O Unknown (likely S-addition of an aldehyde)
830.77 a 27.5 830.7685 58.0313 +C2H4NO Methylisocyanate adduct
833.08 d 27.8 833.0813 64.9696 +HO2S S-Addition of SO2
835.11 a, d 28.2 835.1079 71.0494 +C4H7O S-Addition of crotonaldehyde f
837.10 d,e 27.4 837.1041 77.0380 +C6H5 S-Phenylation
839.78 d,e 27.7 839.7797 85.0647 +C5H9O S-Addition of tiglic aldehyde f
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Table 3. Cont.
Adduct Ret. Time(min)
MIM Observed
(m/z, +3)
Added Mass
(Da)
Suggested Elemental Composition of
Added Mass (to Cys34S−) Annotation
841.10 b,c 28.5 841.0987 89.0183 +C3H5O3
S-Addition of pyruvate or malonate
semialdehyde
841.43 a 27.8 841.4251 90.0013 +C2H4NOS S-Mercaptoacetamide
841.75 a,b,c,d 28.6 841.7529 90.9827 +C2H3O2S S-Addition of mercaptoacetic acid
845.42 a,b,c,d 27.7 845.4249 101.9987 +C3H4NOS S-Addition of Cys (-H2O)
845.75 b 28.6 845.7528 102.9842 +C3H3O2S S-Cys (possibly NH2 → OH, −H2O)
847.10 d 26.7 847.0963 107.0145 +C3H7O2S S-Methylethyl-sulfonylation
847.11 a,b,c 30.2 847.1082 107.0481 +C7H7O S-Addition of benzaldehyde or quinone methide
847.77 a,b 27.3 847.7664 109.0251 Cys34 Adduct with unknown annotation
849.07 a,b,d 28.0 849.0698 112.9353 +HO3S2 S-Addition of S2O3H
850.10 a,b,d 27.9 850.0975 116.0182 +C4H6NOS S-Addition of hCys (-H2O)
851.43 a,b,c,d 26.9 851.4290 120.0109 +C3H6NO2S S-Addition of Cys f
851.76 a,b,c,d 27.8 851.7572 120.9973 +C3H5O3S S-Addition of Cys (NH2→OH)
853.78 a,b 27.7 853.7839 127.0776 Cys34 Adduct with unknown annotation
854.44 d 25.9 854.4428 129.0539 +C6H9O3 S-Addition of BDE
855.44 b 29.0 855.4373 132.0378 +C8H6NO Oxindole
856.10_1 a,b,c,d 27.0 856.1003 134.0250 +C4H8NO2S S-Addition of hCys f
856.10_2 a,b,c,d 27.3 856.1001 134.0244 +C4H8NO2S S-Addition of hCys f
856.43 d 27.2 856.4287 135.0117 +C4H7O3S S-Addition of hCys (NH2→OH)
857.09 c 29.0 857.0876 136.9812 Unknown
857.1 a,b,d 27.4 857.1000 137.0257 Unknown
859.41 d 25.5 859.4085 143.9513 Unknown
860.77 b,c 29.3 860.7717 148.0342 +C4H8NO2S + CH2 S-hCys, plus methylation (not Cys34)
862.09 a,d 26.3 862.0881 151.9901 Not Cys34 adduct
864.08 a,b,d 26.2 864.0772 157.9574 Not Cys34 adduct
864.43 a,b,c,d 27.5 864.4319 159.0198 +C5H7N2O2S S-Addition of CysGly (-H2O)
865.43 a,b,c 28.3 865.4314 162.0176 +C5H8NO3S S-(N-acetyl)Cys
866.76 b 27.0 866.7572 165.9973 +C4H8NO2S2 S-S-hCys trisulfide
870.44 a,b,c,d 26.5 870.4360 177.0319 +C5H9N2O3S S-Addition of CysGly f
872.7309 a 26.7 872.7309 183.9187 Not Cys34 adduct
870.44 a,b,d 27.2 873.4310 186.0187 Unknown
875.11 b,c 27.5 875.1062 191.0409 +C5H9N2O3S + CH2 S-CysGly, plus methylation (not Cys34)
875.42 b 27.7 875.4231 191.9950 Cys34 Adduct with unknown annotation
894.13 b,c 26.1 894.1270 248.1029 Unknown
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Table 3. Cont.
Adduct Ret. Time(min)
MIM Observed
(m/z, +3)
Added Mass
(Da)
Suggested Elemental Composition of
Added Mass (to Cys34S−) Annotation
894.44 a,b,c,d 27.0 894.4426 249.0516 +C8H13N2O5S S-Addition of GluCys f
899.11 c 29.3 899.1140 263.0612 Unknown
913.45 a,b,c,d 26.9 913.4494 306.0722 +C10H16N3O6S S-Addition of GSH f
918.12 c 29.2 918.1222 320.0852 Unknown
927.14 c 27.1 927.1408 347.1412 Unknown
928.78 c 32.2 928.7842 352.0712 Unknown
931.82 b,c,d 25.9 931.8215 361.1881 Unknown
941.16 b 25.3 941.1570 389.1967 Unclear modification site
965.49 b,c,d 25.8 965.4920 462.1994 Unknown
970.16 c 28.1 970.1643 476.2112 Unknown c
974.51 b,d 25.1 974.5068 489.2460 Unknown
976.82 b,c 28.0 976.8205 496.1840 Unknown
981.50 b 25.3 981.4956 510.2126 Cys34 adduct with unknown annotation
Notes: GSH, glutathione; hCys, homocysteine; MIM, monoisotopic mass. a Detected by Grigoryan et al. 2016 [36]. b Detected by Lu et al. 2017 [53].c Detected by Liu et al. 2018 [54]. d
Detected by Grigoryan et al. 2018 [55]. e Adduct was detected in samples that were reduced with tris(2-carboxyethyl)phosphine (TCEP) prior to digestion; reduces all disulfide bonds. f
Annotation confirmed with a synthetic standard.
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Table 4. N-terminal Hb adducts detected using adductomics to date.
[M+H]+ m/z Identity/Precursor a rt (min) Added Mass (Da) to Val-NH Elemental Composition
503.1 b, c Methylation 16.6 15 CH3
517.1 b, c Ethylation 17.9 29 C2H5
519.1 c Unknown 12.3 31 Unknown
519.1 c Unknown 15.7 31 Unknown
533.1 b, c Ethylene oxide 14.1 45 C2H5O
542.1 b Acrylonitrile d 18.0 54 C3H4N
547.1 b, c Carboxy-methylation/Glyoxal 14.2 59 C2H3O2
559.1 b, c Methyl vinyl ketone 16.6 71 C4H7O
560.1 b, c Acrylamide 12.9 72 C3H6NO
561.1 b, c Acrylic acid/Carboxyethylation 14.5 73 C3H5O2
561.1 c Methylglyoxal 12.6 73 C3H5O2
563.1 c Glycidol 12.4 75 C3H7O2
573.1 b, c Ethyl vinyl ketone 18.1 85 C5H9O
576.1 b Glycidamide 12.2 88 C3H6NO2
577.1 b, c Unknown 13.0 89 Unknown
593.1 b, c Unknown 11.3 105 Unknown
595.1 c Unknown 15.1 107 Unknown
595.1 b,c 4-Hydroxybenzyl 17.00 107 C7H7O
615.1 b,c 1-Octen-3-one 22.2 127 C8H15O
617.1 b,c Unknown 14.8 129 Unknown
625.1 b,c Unknown 13.9 137 Unknown
631.1 b,c Unknown 15.2 143 Unknown
651.1 c Unknown 11.2 163 Unknown
659.1 c Unknown 16.4 171 Unknown
686.1 c Unknown 11.2 198 Unknown
Notes: a The names of identified adducts or known/probable precursors are in bold (confirmed with reference adducts). b Detected by Carlsson et al. 2014 [19]. c Detected by Carlsson et
al. 2017 [37]. d Acrylonitrile adducts are typically only observed in samples from smokers.
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The results of an adductomic experiment will be a list of adducts detected, with their molecular
weights, estimated concentrations, and retention times. This is the only information available to
formulate hypotheses about adduct identities. The added mass may be calculated as described above,
by subtracting the m/z of an unmodified precursor molecule, from the adduct m/z. The accuracy of
the calculated added mass will depend on the type of mass spectrometer used, with high resolution
instruments providing more accurate data. Based on the added mass the elemental composition of
the adduct may be suggested. A practical tool to help with this task is the Molecular Formula finder,
provided by ChemCalc (http://www.chemcalc.org/mf_finder) [58]. With a likely composition of the
adduct, the adduct structure or corresponding precursor electrophiles can be suggested. As described
above, electrophiles that form adducts commonly have reactive functional groups, such as activated
double bonds, aldehydes, and epoxides. Such features should be considered when considering
possible precursors, as well as the chemistry of the specific nucleophilic sites and limitations of
the methodology used. One limitation with the present method for Hb adductomics is when the
N-terminal nitrogen atom is blocked for the reaction with the isothiocyanate reagent, as when it is
tertiary or when it is substituted with acyl groups. This exclude ring-closed adducts, e.g., the adduct
from diepoxybutane [59], from being detected. Adducts from isocyanates, carbamoylated N-terminal
valines, could though be detached as hydantoins from Hb after acidification in a procedure similar to
the normal Edman procedure, as has been shown in several studies (e.g., for methylisocyanate [60]
and dimethylformamide [61]). Of the identified or annotated adducts observed to Hb and HSA there
has been very little overlap thus far (when analyzing blood samples from smokers, acrylonitrile,
and ethylene oxide adducts were observed both to Hb and HSA [19,36], and the recently identified
4-hydroxybenzyl Hb adduct may correspond to the unknown HSA adduct with the same annotated
composition C7H7O, added mass 107.0481 Da [52]). This emphasizes the need of several nucleophilic
targets when exploring the adductome.
With adducts of low mass there may be few possible structures and precursors, facilitating
the adduct identification. However, as MWs exceed about 70 Da the numbers of possibilities
increase rapidly, and annotation becomes difficult. To facilitate hypotheses about possible annotations
specialized databases can be used. The simplest of these databases is “Search for Species Data
by Molecular Weight” provided by the National Institute of Standards and Technologies (https:
//webbook.nist.gov/chemistry/mw-ser) [62], which list species based on the input value. Although
there is no specific database for adductomics, the UNIMOD database that lists protein modifications
may be useful (www.unimod.org) [63]. Databases for metabolomics may also contain valuable
information. Among these there are large databases such as the human metabolome database
(http://www.hmdb.ca/metabolites) [64], but also more specific databases such as the Toxic Exposome
Database (T3DB) (http://www.t3db.ca) [65] and the Exposome-Explorer Database (http://exposome-
explorer.iarc.fr) [66] can be relevant for adductomics [67]. Having established one or more candidate
annotations for a given adduct, the next step is to perform literature searches, consider possible
metabolic activations of possible precursors, working backwards to determine whether suspected
adduct precursors have been previously described.
Both Hb and HSA adductomics are performed with gradient-elution reversed-phase
chromatography that separates compounds based on lipophilicity. Thus, the retention times of the
analytes correlate with their lipophilicities, and this information can also be useful in suggesting adduct
identities. For FTH derivatives of Val adducts the theoretical Log P values (calculated using ChemDraw
from CambridgeSoft, Cambridge, MA, USA) correlate with their retention times (with a coefficient
of determination, R2 = 0.88) [57]. By drawing the hypothetical adduct derivatives in ChemDraw and
comparing the theoretical Log Ps with the observed retention times of the investigated unknown
adducts, the hypotheses may be further evaluated prior to initiating the costly and time-consuming
identification. For the FTH derivatives with relatively low MWs generally ranging from about
500–700 Da, this is a very viable strategy while the situation for the larger T3 adducts (MWs > 2432 Da)
is more complex. For such large molecules the retention times are not as affected by small modifications
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and cannot be expected to be as reproducible as for reverse phase separations of small molecules.
Although the chromatographic program includes a 30 min gradient (from 2–45% ACN), the majority
of T3 adducts elute during a 5 min period, indicating the small differences in retention even for large
modifications such as glutathione (added mass of 306 Da) [36].
To confirm adduct identities, reference adducts should be synthesized and compared with the
unknown adducts of interest. Generation of reference adducts can simply involve adding the proposed
precursor electrophiles to either plasma or whole blood/lysate. The concentrations of the electrophiles
and the reaction times necessary to yield sufficient concentrations of the adducts vary depending on the
reactivity and stability of the electrophiles. Detailed experiments for generating reference adducts have
previously been published by Grigoryan et al. [36,55,56] for HSA adducts, and Carlsson et al. [19,57] for
Hb adducts. Following incubations with electrophiles the samples should be processed and analyzed
according to the respective methods. The synthetic adducts should then be compared with the
unidentified adducts observed concurrently in untreated human samples to minimize methodological
and instrumental variations. The comparison should be done with regard to m/z of the precursor ions,
fragmentation patterns (MS2) as well as retention times. The identification process is summarized in
the form of a flowchart in Figure 4.High-Throughput 2019, 8, x FOR PEER REVIEW 12 of 17 
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7. Conclusions
The concept of protein adductomics was introduced nearly a decade ago. Since then the
methodologies have been refined for the current generation of instrumentation and adapted to
showcase the strengths and possibilities of adductomics. Many previously unknown adducts have
been detected, and many of them have been identified. When comparing the present methodologies
for HSA and Hb adductomics, the HSA method is more versatile and suited for high-throughput
studies. By analyzing tryptic digests of HSA this method is truly untargeted and although adducts to
Cys34 have been the primary focus to date, adducts to other nucleophilic sites in HSA (e.g., Lys199)
may be detected simultaneously in a single LC-MS run. Other advantages of HSA adductomics is
the low sample volumes needed (5 µL) and the streamlined selection of adducts using the in-house
software. The method for Hb adductomics is limited to N-terminal Hb adducts and require relatively
large sample volumes (250 µL), and will benefit from lower detection levels with more sensitive
MS instrumentation than used in the published adductomics work. This methodology, however,
benefits from the relatively small molecules resulting from the derivatization of N-terminal adducts,
that are advantageous in the identification of unknown adducts. The FTH derivatives separate well
using reversed phase chromatography, with highly reproducible retention times, and give distinct MS2
spectra. The minimal overlap of the adducts so far detected and identified with the different methods
highlights the need to analyze several nucleophilic sites to explore the full adductome. In the small
field of adductomics the two methods described in this review are the two best suited methods for
analyzing large number of samples, even though the numbers of samples that can be analyzed during
a certain period are limited compared to methods used, for example, for metabolomics.
The constant improvement of MS instrumentation will benefit adductomics by decreasing
detection limits and improving mass accuracies. The most challenging aspect of adductomics is,
however, the quantification of unknown adducts. Hemoglobin adductomics rely on a more traditional
approach with internal standard calibration and report estimated adducts levels assuming similar
responses for all adducts. Human serum albumin adductomics employs an innovative housekeeping
peptide to normalize peak areas for the amounts of HSA in the digests. Both approaches acknowledge
the impossible task of giving accurate quantitative estimates of unknowns, and for the purposes
of adductomics they work well, meaning that the relative concentrations of a set of adducts in a
population of samples can be obtained for preliminary evaluations. If follow-up studies heighten
interest in these adducts, then they can be identified and standardized for subsequent targeted analyses.
Another challenging aspect of adductomics is formation of artifacts from storing and processing of
samples. In the case of HSA adductomics the digestion procedure could potentially expose the
nucleophilic sites in the protein for electrophiles present in the samples. For Hb adductomics the
derivatization procedure could potentially form byproducts or chemically affect adducts. To control
for such processes, various control experiments may be performed (cf. Carlsson 2014 [19]), but it is
not likely that artefact formation for certain adducts, for instance during storage [68], may be fully
controlled. Thankfully, it can be assumed that the extent of such artifact formation should be the
same for all samples processed in a given study, e.g., from disease cases and concurrent controls,
thereby reducing the likelihood of false positives in the statistical analysis.
As a complement to the HSA adductomics method we are currently investigating the analysis of
intact HSA isoforms in plasma samples, using a time-of-flight MS. When analyzing the intact protein,
the sample preparation prior to the MS analysis is minimal, as is the risk of introducing artifacts.
Cysteine 34 of HSA is easily oxidized and the analysis of the intact protein provides valuable insights
about the state of HSA in samples, prior to digestion. By comparing the two approaches, using
both bottom-up and top-down proteomic data of HSA in plasma samples, a more complete view of
HSA and the various modified forms is gained. An important goal of adductomics is to provide a
deeper understanding of the underlying chemistry describing how proteins are modified by reactive
compounds in vivo. With the methods described in this review we have increased our understanding
of this fascinating aspect of biological chemistry.
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AA acrylamide
ACN acetonitrile
DIA data independent acquisition
DDA data-dependent acquisition
FITC fluorescein isothiocyanate
FTH fluorescein thiohydantoin
Hb hemoglobin
HRMS high-resolution mass spectrometry
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HSA human serum albumin
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